Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 6, 2025MedCommOpen Access

Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

LWLiang WangHLHan LiangWGWei Gao

Discussion

Loading...

Member takes

Overview

Innovative ctDNA assay predicts postoperative recurrence in solid tumors, suggesting improved decision-making in clinical settings.

Key Points

  • Circulating tumor DNA monitoring accurately predicts postoperative recurrence across multiple solid tumors.
  • The ctDNA assay demonstrated a prognostic value with a detection limit of 0.005% and 100% specificity.
  • Genomic profiling of tumor tissue informs the personalized panel design for the assay's performance.
  • This personalized monitoring approach enhances clinical decision-making and early detection of recurrent disease.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69337d02b3f947a0a125a90bhttps://doi.org/10.1002/mco2.70483
View Full Paper
Ask AI
Bookmark
Share